Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $83 to $86.